SAF 312

Drug Profile

SAF 312

Alternative Names: SAF312

Latest Information Update: 15 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Non-opioid analgesics; Quinazolinones; Urologics
  • Mechanism of Action TRPV cation channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Postoperative pain
  • Discontinued Neurogenic bladder

Most Recent Events

  • 21 Feb 2018 Novartis completes phase-II clinical trials in Postoperative pain (Ocular pain) in USA (Ophthalmic) (NCT02961062)
  • 14 Nov 2016 Novartis Pharmaceuticals plans a phase II trial for Postoperative Pain (Ocular pain) in USA (NCT02961062)
  • 22 Feb 2013 Novartis terminates a phase II trial in Neurogenic bladder in Belgium, Germany, Netherlands and Switzerland (NCT01598103)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top